01 September 2005
Gelstat Migraine((R)) (sublingually administered feverfew and ginger compound) for acute treatment of migraine when administered during the mild pain phase.
Roger K. Cady, Curtis P. Schreiber, Mary E. Beach, Carolyn C. HartMed Sci Monit 2005; 11(9): PI65-69 :: ID: 428456
Abstract
Background: Treatment of migraine headaches is often delayed due to assessingthe potential severity of an evolving headache or anticipating unwanted consequences from prescriptionmedication. Studies have demonstrated improved pain-free response when prescription treatments are takenduring the mild headache phase of a migraine. This study was designed to evaluate the efficacy of anOTC product, GelStat Migraine((R)), when taken in the early, mild pain phase of migraine. Material/Methods:An open-label study enrolling 30 subjects, male and female, with a one-year history of migraine meetingIHS diagnostic criteria with or without aura, 2-8 migraines per month and 15 headache days per month.Inclusion required having migraines that consistently started at mild and worsened to moderate or severe,if untreated, in at least 75% of attacks. Subjects also had to be able to distinguish migraine from non-migraineheadaches and reliably identify migraine early in the course of an attack. One headache was treated inthe mild pain phase with GelStat Migraine((R)), a combination of feverfew and ginger. Results: 29 evaluablesubjects completed the study, all treating at mild pain. Two hours after treatment, 48% were pain-freewith 34% reporting a headache of only mild severity. 29% reported a recurrence within 24 hours. Sideeffects were minimal and not serious. 59% of subjects were satisfied with Gelstat Migraine((R)) therapyand 41% preferred GelStat Migraine((R)) or felt it was equal to their pre-study medication. Conclusions:GelStat Migraine((R)) is effective as a first line abortive treatment for migraine when initiated earlyduring the mild headache phase.
Keywords: Administration, Sublingual, Analgesics - therapeutic use, Ginger, Migraine Disorders - physiopathology, Nonprescription Drugs, Pain - physiopathology, Phytotherapy, Tanacetum parthenium
978 51
Editorial
01 November 2023 : Editorial
Editorial: Factors Driving New Variants of SARS-CoV-2, Immune Escape, and Resistance to Antiviral Treatments as the End of the COVID-19 Pandemic is DeclaredDOI: 10.12659/MSM.942960
Med Sci Monit 2023; 29:e942960
In Press
30 Nov 2023 : Review article
Decoding the Neurological Sequelae of General Anesthesia: A ReviewMed Sci Monit In Press; DOI:
30 Nov 2023 : Clinical Research
Enhanced Pain Relief and Muscle Growth in Individuals with Low Back Instability: The Impact of Blood Flow R...Med Sci Monit In Press; DOI:
29 Nov 2023 : Clinical Research
Comparative Analysis of Intramedullary Nail versus Plate Fixation for Fibula Fracture in Supination Externa...Med Sci Monit In Press; DOI:
29 Nov 2023 : Clinical Research
Impact of COVID-19 on Academic Burnout among Medical College Students in China: Findings from a Web-Based S...Med Sci Monit In Press; DOI:
Most Viewed Current Articles
13 Nov 2021 : Clinical Research
Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...DOI :10.12659/MSM.932788
Med Sci Monit 2021; 27:e932788
30 Dec 2021 : Clinical Research
Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...DOI :10.12659/MSM.935379
Med Sci Monit 2021; 27:e935379
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
08 Mar 2022 : Review article
A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...DOI :10.12659/MSM.936292
Med Sci Monit 2022; 28:e936292